Eplerenone – the facts speak for themselves Review article
Article Sidebar
Published:
Mar 31, 2018
Keywords:
eplerenone, heart failure, side effects
Main Article Content
Abstract
Eplerenone is a relatively selective mineralocorticoid receptor antagonist. It inhibits the neurohormonal axis of renin–angiotensin–aldosterone, which is the cause of progression of heart failure. The drug is used in the treatment of heart failure and in patients after myocardial infarction with impaired left ventricular systolic function. The low affinity of eplerenone for androgen and progesterone receptors results in good tolerance of the drug and a small amount of side effects.
Article Details
How to Cite
Dyrla , W., & Kuch , M. (2018). Eplerenone – the facts speak for themselves. Medycyna Faktow (J EBM), 11(1(38), 42-44. https://doi.org/10.24292/01.MF.0118.6
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Krum H., Nolly H., Workman D. et al.: Efficacy of eplerenone added to renin–angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
2. Kapłon-Cieślicka A., Filipiak K.J.: Eplerenon – co wiadomo o tym leku na początku 2009 roku? Choroby Serca i Naczyń 2009; 6(1): 26-36.
3. Szymański F.M., Filipiak K.J., Mamcarz A. et al.: Eplerenon w codziennej praktyce – aktualne miejsce w terapii i perspektywy stosowania w Polsce. Stanowisko ekspertów wsparte prze Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Folia Cardiologica 2015; 10(4): 288-293.
4. Pitt B., Remme W., Zannad F. et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
5. Zannad F., McMurray J.J., Krum H. et al.; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
2. Kapłon-Cieślicka A., Filipiak K.J.: Eplerenon – co wiadomo o tym leku na początku 2009 roku? Choroby Serca i Naczyń 2009; 6(1): 26-36.
3. Szymański F.M., Filipiak K.J., Mamcarz A. et al.: Eplerenon w codziennej praktyce – aktualne miejsce w terapii i perspektywy stosowania w Polsce. Stanowisko ekspertów wsparte prze Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Folia Cardiologica 2015; 10(4): 288-293.
4. Pitt B., Remme W., Zannad F. et al.: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
5. Zannad F., McMurray J.J., Krum H. et al.; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.